Effectiveness and Safety of Interferon-Free Direct-Acting Antiviral Hepatitis C Virus Therapy in HIV/Hepatitis C Virus Coinfected Individuals: Results From a Pan-European Study.

Anilides Antiviral Agents / administration & dosage Benzimidazoles Coinfection / drug therapy Cyclopropanes Female Fluorenes HIV Infections / drug therapy Hepacivirus Hepatitis C / complications Hepatitis C, Chronic / drug therapy Humans Interferons / administration & dosage Lactams, Macrocyclic Male Middle Aged Proline / analogs & derivatives Ribavirin / administration & dosage Simeprevir / administration & dosage Sofosbuvir / administration & dosage Sulfonamides Sustained Virologic Response Valine

Journal

Journal of acquired immune deficiency syndromes (1999)

ISSN: 1944-7884

Titre abrégé: J Acquir Immune Defic Syndr

Pays: United States

ID NLM: 100892005

Informations de publication

Date de publication:
01 02 2021

Historique:

received: 19 05 2020

accepted: 05 10 2020

pubmed: 21 10 2020

medline: 6 8 2021

entrez: 20 10 2020

Statut: ppublish

Résumé

To investigate the effectiveness, safety, and reasons for premature discontinuation of direct-acting antivirals (DAAs) in a diverse population of HIV/hepatitis C virus (HCV) coinfected individuals in Europe. All HIV/HCV coinfected individuals in the EuroSIDA study that started interferon free DAA treatment between January 6, 2014, and January 3, 2018, with ≥12 weeks of follow-up after treatment stop were included in this analysis. Sustained virological response (SVR) was defined as a negative HCV-RNA result ≥12 weeks after stopping treatment (SVR12). Logistic regression was used to explore factors associated with SVR12. 1042 individuals started interferon-free DAA treatment after 1/6/2014 and were included, 862 (82.2%) had a known response to treatment, and 789 [91.5%, 95% confidence interval (CI): 89.7 to 93.4] of which achieved SVR12. There were no differences in SVR12 across regions of Europe (P = 0.84). After adjustment, the odds of achieving SVR12 was lower in individuals that received sofosbuvir/simeprevir ± ribavirin (RBV) [adjusted odds ratio 0.21 (95% CI: 0.08 to 0.53)] or ombitasvir/paritaprevir/dasabuvir ± RBV [adjusted odds ratio 0.46 (95% CI: 0.22 to 1.00)] compared with sofosbuvir/ledipasvir ± RBV. Forty-three (4.6%) individuals had one or more components of their HCV regimen stopped early, most commonly because of toxicity (n = 14); of these 14, 11 were treated with ribavirin. Increased bilirubin was the most common grade 3 or 4 laboratory adverse event (n = 15.3%) and was related to treatment with atazanavir and ribavirin. Our findings from real-world data on HIV/HCV coinfected individuals across Europe show DAA treatment is well tolerated and that high rates of SVR12 can be achieved in all regions of Europe.

Identifiants

DOI: 10.1097/QAI.0000000000002541 PMID: 33079903

pubmed: 33079903

pii: 00126334-202102010-00020

doi: 10.1097/QAI.0000000000002541

doi:

Substances chimiques

Anilides 0

Antiviral Agents 0

Benzimidazoles 0

Cyclopropanes 0

Fluorenes 0

Lactams, Macrocyclic 0

Sulfonamides 0

ledipasvir, sofosbuvir drug combination 0

ombitasvir 2302768XJ8

Ribavirin 49717AWG6K

Interferons 9008-11-1

Proline 9DLQ4CIU6V

Simeprevir 9WS5RD66HZ

Valine HG18B9YRS7

paritaprevir OU2YM37K86

Sofosbuvir WJ6CA3ZU8B

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

Pagination

248-257

Informations de copyright

Déclaration de conflit d'intérêts

The authors have no conflicts of interest to disclose.

Références

World Health Organisation. Global health observatory data (GHO). Available at: https://www.who.int/gho/hiv/en/ . Accessed August 29, 2020.

Platt L, Easterbrook P, Gower E, et al. Prevalence and burden of HCV co-infection in people living with HIV: a global systematic review and meta-analysis. Lancet Infect Dis. 2016;16:797–808.

Graham CS, Baden LR, Yu E, et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis. 2001;33:562–569.

Arends JE, Lieveld FI, Boeijen LL, et al. Natural history and treatment of HCV/HIV coinfection: is it time to change paradigms? J Hepatol. 2015;63:1254–1262.

Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection: Recommendations for a Public Health Approach—ed. Geneva, Switzerland: World Health Organization, 2016. Available at: https://www.who.int/hiv/pub/arv/arv-2016/en/ . Accessed March 23, 2019.

European AIDS Clinical Society Guidelines Version 9.1, 2018 Available at: http://www.eacsociety.org/files/2018_guidelines-9.1-english.pdf .

Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 2014;370:1889–1898. Accessed October 29, 2019.

Kwo PY, Poordad F, Asatryan A, et al. Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis. J Hepatol. 2017;67:263–271.

Sulkowski MS, Gardiner DF, Rodriguez-Torres M, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med. 2014;370:211–221.

Wyles DL, Ruane PJ, Sulkowski MS, et al. Daclatasvir plus sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med. 2015;373:714–725.

Rockstroh JK, Nelson M, Katlama C, et al. Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial. Lancet HIV. 2015;2:e319–e327.

Rockstroh JK, Lacombe K, Viani RM, et al. Efficacy and safety of glecaprevir/pibrentasvir in patients coinfected with hepatitis C virus and human immunodeficiency virus type 1: the EXPEDITION-2 study. Clin Infect Dis. 2018;67:1010–1017.

Naggie S, Cooper C, Saag M, et al. Ledipasvir and sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med. 2015;373:705–713.

Berenguer J, varez-Pellicer J, Martin PM, et al. Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus. Hepatology. 2009;50:407–413.

Kovari H, Rauch A, Kouyos R, et al. Hepatitis C infection and the risk of non-liver-related morbidity and mortality in HIV-infected persons in the Swiss HIV cohort study. Clin Infect Dis. 2017;64:490–497.

Mocroft A, Lundgren J, Gerstoft J, et al. Clinical outcomes in persons coinfected with human immunodeficiency virus and hepatitis C virus: impact of hepatitis C virus treatment. Clin Infect Dis. 2019;70:2131–2140.

Combating Hepatitis B and C to Reach Elimination by 2030. Geneva, Switzerland: World Health Organization, 2016. Available at: https://www.who.int/hepatitis/publications/hep-elimination-by-2030-brief/en/ . Accessed September 22, 2019.

Beguelin C, Suter A, Bernasconi E, et al. Trends in HCV treatment uptake, efficacy and impact on liver fibrosis in the Swiss HIV Cohort Study. Liver Int. 2018;38:424–431.

Berenguer J, Gil-Martin A, Jarrin I, et al. All-oral direct-acting antiviral therapy against hepatitis C virus (HCV) in human immunodeficiency virus/HCV-coinfected subjects in real-world practice: Madrid coinfection registry findings. Hepatology. 2018;68:32–47.

Bhattacharya D, Belperio PS, Shahoumian TA, et al. Effectiveness of all-oral antiviral regimens in 996 human immunodeficiency virus/hepatitis C virus genotype 1-coinfected patients treated in routine practice. Clin Infect Dis. 2017;64:1711–1720.

Piroth L, Wittkop L, Lacombe K, et al. Efficacy and safety of direct-acting antiviral regimens in HIV/HCV-co-infected patients—French ANRS CO13 HEPAVIH cohort. J Hepatol. 2017;67:23–31.

Boesecke C, Ingiliz P, Berger F, et al. Liver cirrhosis as a risk factor for direct-acting antiviral therapy failure in real-life hepatitis C virus/human immunodeficiency virus coinfection. Open Forum Infect Dis. 2017;4:ofx158.

Laut K, Kirk O, Rockstroh J, et al. The EuroSIDA study: 25 years of scientific achievements. HIV Med. 2020;21:71–83.

Mauss S, Pol S, Buti M, et al. Late presentation of chronic viral hepatitis for medical care: a consensus definition. BMC Med. 2017;15:92.

Grint D, Peters L, Rockstroh JK, et al. Liver-related death among HIV/hepatitis C virus-co-infected individuals: implications for the era of directly acting antivirals. AIDS. 2015;29:1205–1215.

Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, Corrected Version 2.1. National Institute of Allergy and Infectious Diseases, US Department of Health and Human Services, 2017. Available at: https://rsc.niaid.nih.gov/sites/default/files/daidsgradingcorrectedv21.pdf . Accessed April 22, 2019.

European AIDS Clinical Society Guidelines Version 10.0, 2019 Available at: https://www.eacsociety.org/guidelines/eacs-guidelines/eacs-guidelines.html . Accessed March 23, 2020.

Prescribing Information for REBETOL, MERCK, 2020 Available at: https://www.merck.com/product/usa/pi_circulars/r/rebetol/rebetol_pi.pdf . Accessed February 10, 2020.

Prescribing Information for REYATAZ, Bristol-Myers Squibb, 2018 Available at: https://packageinserts.bms.com/pi/pi_reyataz.pdf . Accessed February 10, 2020.

Sulkowski MS, Eron JJ, Wyles D, et al. Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial. JAMA. 2015;313:1223–1231.